Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
abbreviated, Alaven, aminosalicylate, analyze, analyzed, ANDA, andC, Answer, apriso, Arcolab, arisen, auction, Australia, banker, bear, Bergamo, bioavailability, bioequivalence, black, box, boxed, budesonide, Catalent, CDC, citing, climate, collateral, collateralize, confirming, context, contrary, corroborated, Cosma, counter, Counterclaim, Court, crofelemer, Debtor, declaratory, denial, denied, deposit, designee, District, economy, EITF, eleven, embedded, ensuing, exceeding, expressly, family, foam, foregoing, fundamental, gastroesophageal, Glenmark, goal, guide, headcount, HIV, indenture, India, injury, interruption, IV, Jersey, junior, Kentucky, knowledge, lawsuit, lead, linked, Metozolv, mid, mitigation, mix, Mumbai, Nap, Napo, neuropsychiatric, nonrefundable, Obama, OSP, Paragraph, permission, Pharmatel, pivotal, political, preceding, predecessor, prevalent, principle, protocol, PTY, rank, redeem, redeemed, refinanced, repurchase, repurchased, retrospectively, saleable, scientifically, semiannually, South, spectrum, subordinated, substantive, suitable, suspended, Swindon, thereof, TID, timeline, treasury, trustee, unamortized, unenforceability, vigorously, waive, Winchester, Wuppertal, Zealand
Removed:
acceleration, achieved, area, assuming, Austria, belief, deliver, Denmark, diseased, Finland, forma, GAAP, Iceland, implemented, Ireland, light, Luxembourg, merger, model, negotiation, Norway, predominate, pro, ranging, Republic, Schwartz, Schwarz, site, stocking, studying, Sweden, thereon, training, UCB, unqualified, unvested, utility, volatility
Filing tables
Filing exhibits
- 10-K Annual report
- 10.64 Collaboration Agreement Between Napo Pharmaceuticals and Salix
- 10.65 Manufacturing and Supply Agreement Between Salix and Glenmark
- 21.1 Salix Pharmaceuticals, LTD. Subsidiaries
- 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Consent of Ernst & Young LLP
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
Salix Pharmaceuticals similar filings
Filing view
External links
EXHIBIT 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-110942) of Salix Pharmaceuticals, Ltd., |
| (2) | Registration Statement (Form S-8 No. 333-126685) pertaining to the InKine Pharmaceutical Company, Inc. 1993 Stock Option Plan, the InKine Pharmaceutical Company, Inc. 1997 Consultant Stock Option Plan, the InKine Pharmaceutical Company, Inc. 1999 Equity Compensation Plan, and the InKine Pharmaceutical Company, Inc. 2004 Equity Compensation Plan, |
| (3) | Registration Statements (Form S-8 Nos. 333-126290, 333-135268 and 333-151658) pertaining to the 2005 Stock Plan of Salix Pharmaceuticals, Ltd., and |
| (4) | Registration Statements (Form S-8 Nos. 333-116675, 333-96771, 333-63604, 333-61497, and 333-47586) pertaining to the 1996 Stock Option Plan, as amended; |
of our report dated March 9, 2007, with respect to the consolidated financial statements and schedule of Salix Pharmaceuticals, Ltd., included in this Annual Report (Form 10-K) of Salix Pharmaceuticals, Ltd.
/s/ Ernst & Young LLP
Raleigh, North Carolina
March 11, 2009